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Background
Hepatitis C Virus (HCV) is epidemic in Egypt and causes
chronic hepatitis. Anti-HCVtherapy (IFN-a and Riba-
virin) is only effective in 60% of patients with chronic
HCV infection. This failure which is often associates with
suppression of immunity results in progression of the
disease and the development of hepatocellular carcinoma.
Recent studies including ours have shown a positive cor-
relation between accumulation of myeloid derived sup-
pressor cells (MDSCs) and suppressed immunity in
cancer and other diseases.
Aim
To assess the frequency of myeloid cells, including
MDCS and dendritic cells (DCs) in chronic HCV patients
and correlate it with the responses of the patients to IFN-
a-bases therapy.
Methods
Peripheral blood was drawn from 80 patients with chronic
HCV infection (mean age = 41.5 ± 6.51 years; male/female:
60/20) and from10 healthy volunteers (mean age = 28.5 ±
3.81 years; male/female: 8/2). The study was conducted
from January 2011 to April 2013. The patients were cate-
gorized into responders and non-responders based on
viral titer and the clinical data was collected and analyzed
for each patient. Frequency of the cells was assessed by
flow cytometry and IL-2 was assessed by ELISA.
Results
We defined MDSC population as Lin-/HLA-DR-/CD33
+/CD11b+. We also found increases in the frequency of
MDSC. The high levels of MDSC was associated with
increases in the frequency of DCs and T cells (CD4+ and
CD8+), as well as with the differential count of lympho-
cytes, and monocytes. It was associated, however, with
decreases in the total numbers of the total number of
white blood cells, granulocytes, and platelets. The total
Bilirubin level, and hemoglobin, in all IFN-a Responders
and Non-Responders when compared with healthy
donors. Interestingly, the frequencies of MDSC and DCs
in IFN-a-responders were lower than in those in non-
responders. More interestingly, the levels of MDSC mea-
sured 4-6 months of IFN-a treatment of responders was
much lower than those during treatment. We found that
there was no correlation between MDSCs, and the liver
enzymes AST and ALT.
Conclusions
Chronic HCV patients showed high levels of MDSCs
regardless IFN-a therapy. The responders have the ten-
dency of lower MDSC levels than non-responders. MDSCs
can use as biomarker of responsiveness to IFN-based ther-
apy. As such, identifying novel effective therapeutic that
can target MDSCs would improve clinical outcomes in
HCV patients.
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